174 related articles for article (PubMed ID: 26365524)
1. Therapy of hepatitis C by direct-acting anti-virals: the end of HCV in dialysis population?
Fabrizi F; Messa P
Expert Rev Clin Pharmacol; 2015; 8(6):785-93. PubMed ID: 26365524
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis.
Li T; Qu Y; Guo Y; Wang Y; Wang L
Liver Int; 2017 Jul; 37(7):974-981. PubMed ID: 27943605
[TBL] [Abstract][Full Text] [Related]
3. New and Emerging Evidence on the Use of Second-Generation Direct Acting Antivirals for the Treatment of Hepatitis C Virus in Renal Impairment.
Sorbera MA; Friedman ML; Cope R
J Pharm Pract; 2017 Jun; 30(3):359-365. PubMed ID: 26902648
[TBL] [Abstract][Full Text] [Related]
4. A review of direct-acting antivirals for the treatment of hepatitis C in patients with advanced chronic kidney disease.
Maruyama A; Partovi N; Yoshida EM; Erb SR; Azalgara VM; Hussaini T
Nephrol Dial Transplant; 2017 Jan; 32(1):35-41. PubMed ID: 26481484
[TBL] [Abstract][Full Text] [Related]
5. [Novel treatments for hepatitis C virus infection in chronic kidney disease].
Fabrizi F; Messa P
G Ital Nefrol; 2016; 33(4):. PubMed ID: 27545640
[TBL] [Abstract][Full Text] [Related]
6. Direct-acting antivirals for hepatitis C virus in patients on maintenance dialysis.
Fabrizi F; Donato FM; Messa P
Int J Artif Organs; 2017 Oct; 40(10):531-541. PubMed ID: 28708211
[TBL] [Abstract][Full Text] [Related]
7. New treatment for hepatitis C in chronic kidney disease, dialysis, and transplant.
Fabrizi F; Martin P; Messa P
Kidney Int; 2016 May; 89(5):988-994. PubMed ID: 27083277
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.
Everson GT; Sims KD; Rodriguez-Torres M; Hézode C; Lawitz E; Bourlière M; Loustaud-Ratti V; Rustgi V; Schwartz H; Tatum H; Marcellin P; Pol S; Thuluvath PJ; Eley T; Wang X; Huang SP; McPhee F; Wind-Rotolo M; Chung E; Pasquinelli C; Grasela DM; Gardiner DF
Gastroenterology; 2014 Feb; 146(2):420-9. PubMed ID: 24184132
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Hepatitis C Virus Infection in Dialysis Patients.
Kikuchi K
Contrib Nephrol; 2018; 196():119-122. PubMed ID: 30041215
[TBL] [Abstract][Full Text] [Related]
10. Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis.
Majumdar A; Kitson MT; Roberts SK
Aliment Pharmacol Ther; 2016 Jun; 43(12):1276-92. PubMed ID: 27087015
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of sofosbuvir-based treatment of acute hepatitis C in end-stage renal disease patients undergoing haemodialysis.
He YL; Yang SJ; Hu CH; Dong J; Gao H; Yan TT; Liu JF; Yang Y; Ren DF; Zhu L; Zhao YR; Chen TY
Aliment Pharmacol Ther; 2018 Feb; 47(4):526-532. PubMed ID: 29250808
[TBL] [Abstract][Full Text] [Related]
12. Chemical genetics-based development of small molecules targeting hepatitis C virus.
Jin G; Lee J; Lee K
Arch Pharm Res; 2017 Sep; 40(9):1021-1036. PubMed ID: 28856597
[TBL] [Abstract][Full Text] [Related]
13. Acute interstitial nephritis following treatment with direct-acting antiviral agents in hepatitis C virus-infected patients: A case series.
Duque JC; Dejman A; Venkat V; Hernandez M; Roth D; Ladino MA
Clin Nephrol; 2021 Jan; 95(1):22-27. PubMed ID: 32909545
[TBL] [Abstract][Full Text] [Related]
14. Direct acting anti-viral medications for hepatitis C: Clinical trials in patients with advanced chronic kidney disease.
Bruchfeld A; Lindahl K
Semin Dial; 2019 Mar; 32(2):135-140. PubMed ID: 30475421
[TBL] [Abstract][Full Text] [Related]
15. Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use.
Bagaglio S; Uberti-Foppa C; Morsica G
Drugs; 2017 Jul; 77(10):1043-1055. PubMed ID: 28497432
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C Treatment in Chronic Kidney Disease Patients: The Kidney Disease Improving Global Outcomes Perspective.
Jadoul M; Martin P
Blood Purif; 2017; 43(1-3):206-209. PubMed ID: 28114144
[TBL] [Abstract][Full Text] [Related]
17. Sofosbuvir as backbone of interferon free treatments.
Bourlière M; Oules V; Ansaldi C; Adhoute X; Castellani P
Dig Liver Dis; 2014 Dec; 46 Suppl 5():S212-20. PubMed ID: 25453869
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C virus infection and chronic kidney disease: Time for reappraisal.
Cacoub P; Desbois AC; Isnard-Bagnis C; Rocatello D; Ferri C
J Hepatol; 2016 Oct; 65(1 Suppl):S82-S94. PubMed ID: 27641990
[TBL] [Abstract][Full Text] [Related]
19. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis.
Aqel BA; Pungpapong S; Leise M; Werner KT; Chervenak AE; Watt KD; Murphy JL; Ryland K; Keaveny AP; McLemore R; Vargas HE
Hepatology; 2015 Oct; 62(4):1004-12. PubMed ID: 26096332
[TBL] [Abstract][Full Text] [Related]
20. Effects of chronic kidney disease stage 4, end-stage renal disease, or dialysis on the plasma concentrations of ombitasvir, paritaprevir, ritonavir, and dasabuvir in patients with chronic HCV infection: pharmacokinetic analysis of the phase 3 RUBY-I and RUBY-II trials.
Shuster DL; Menon RM; Ding B; Khatri A; Li H; Cohen E; Jewett M; Cohen DE; Zha J
Eur J Clin Pharmacol; 2019 Feb; 75(2):207-216. PubMed ID: 30291369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
